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Background: The serine protease Granzyme B (GzB) is primarily expressed by cytotoxic T lymphocytes and natural killer
cells, and functions in allowing these cells to induce apoptosis in virally-infected or transformed cells. Cancers of both
lymphoid and non-lymphoid origin also express GzB, and in some cases this expression has been linked to pathogenesis
or sensitizing tumour cells to cell death. For example, GzB expression in urothelial carcinoma was implicated in
promoting tumour cell invasion, whereas its expression in nasal-type NK/T lymphomas was found to correlate
with increased apoptosis. GzB expression is also a hallmark of the non-Hodgkin lymphoma, anaplastic lymphoma
kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL). Given the fact that ALK+ ALCL exhibits high levels of
apoptosis and is typically responsive to conventional chemotherapy, we examined whether GzB expression might
play a role in sensitizing ALK+ ALCL tumour cells to apoptosis.
Methods: ALK+ ALCL cell lines stably expressing GzB or non-targeting (control) shRNA were generated and apoptosis
was examined by anti-PARP western blotting and terminal deoxynucleotidyl transferase dUTP nick end labelling. Both
spontaneous apoptosis and apoptosis in response to treatment with staurosporine or doxorubicin were investigated. In
order to assess whether additional granzymes might be important in promoting cell death in ALK+ ALCL, we examined
whether other human granzymes were expressed in ALK+ ALCL cell lines using reverse-transcriptase PCR and western
blotting.
Results: Expression of several GzB shRNAs in multiple ALK+ ALCL cell lines resulted in a significant decrease in GzB
levels and activity. While spontaneous apoptosis was similar in ALK+ ALCL cell lines expressing either GzB or control
shRNA, GzB shRNA-expressing cells were less sensitive to staurosporine or doxorubicin-induced apoptosis as evidenced
by reduced PARP cleavage and decreased DNA fragmentation. Furthermore, we found that GzB is the only granzyme
that is expressed at significant levels in ALK+ ALCL cell lines.
Conclusions: Our findings are the first to demonstrate that GzB expression sensitizes ALK+ ALCL cell lines to
drug-induced apoptosis. This suggests that GzB expression may be a factor contributing to the favourable
response of this lymphoma to treatment.
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Granzyme B (GzB) is a serine protease found in the cyto-
plasmic granules of cytotoxic T lymphocytes (CTLs) and
natural killer (NK) cells. It is released along with other
granule proteins such as the pore-forming protein perforin,
into the immunological synapse where it is translocated
into virally-infected or transformed cells to initiate apop-
tosis [1,2]. GzB primarily initiates apoptosis either through
direct proteolytic processing and activation of initiator
(caspase 8) or executioner (caspases 3 and 7) caspases, or
through disruption of mitochondrial outer membrane po-
tential via cleavage of the Bid protein [2]. GzB may also
contribute to apoptosis induction through the cleavage of
other cellular substrates including nuclear lamin B, poly
(ADP-ribose) polymerase (PARP), and inhibitor of caspase-
activated DNase (ICAD) [2]. GzB also has substrates out-
side the cell, and may gain access to the extracellular space
as a result of leakage from the immunological synapse or
by direct secretion from cytotoxic cells [3,4]. These sub-
strates include extracellular matrix (ECM) proteins such as
vitronectin, laminin, fibronectin, decorin, and biglycan
[5-7]. Cleavage of these proteins by GzB has been impli-
cated in detaching adherent cells bound to these proteins
[5], promoting the migration of cells through matrigel [6],
and releasing matrix-bound cytokines [7].
Not surprisingly, GzB is expressed in a number of T/NK
cell neoplasms including anaplastic lymphoma kinase-
positive, anaplastic large cell lymphoma (ALK+ALCL)
[8-11], ALK- ALCL [8-10], and nasal-type NK/T cell
lymphoma [10,12], as well as other lymphoid cancers in-
cluding some Hodgkin lymphoma [13-15] and multiple
myeloma [16]. GzB expression can also be found in cell
lines and/or primary tumours of non-lymphoid origin in-
cluding acute myeloid leukemia [17], prostate cancer [18]
and some carcinomas of the breast [19] and urothelium
[6]. While the significance, if any, of GzB expression in
most of these malignancies has yet to be firmly established,
in urothelial carcinoma GzB expression correlates with in-
creased invasiveness and epithelial-to-mesenchymal transi-
tion of tumour cells [6]. More importantly, this study
demonstrated that in GzB-expressing bladder cancer cell
lines, GzB promotes the invasion of these cells through
matrigel, presumably through the degradation of ECM
proteins within the matrigel [6]. In contrast, GzB expres-
sion in some cancers has been reported to be detrimental
to tumour cells. In nasal-type NK/T cell lymphomas, GzB
expression correlates with increased apoptosis, and leakage
of GzB out of cytotoxic vesicles in the HANK-1 NK/T cell
lymphoma cell line was argued to contribute to high levels
of spontaneous apoptosis in this cell line [12]. Similarly,
prostate cancer cell lines treated with resveratrol and radi-
ation up-regulate GzB and perforin, and increased expres-
sion of these proteins was postulated to contribute to
tumour cell apoptosis [18].ALK+ALCL is an aggressive non-Hodgkin T cell lymph-
oma that is most prevalent in children and young adults
[20]. This lymphoma expresses GzB in cytotoxic granules
along with perforin and T cell-restricted intracellular
antigen-1 (TIA-1) [8-11]. Lymphoma cells typically possess
T cell receptor gene rearrangements [8,11,21]; however, the
expression of many T cell markers is variable in ALK+
ALCL [11,21,22]. A defining feature of ALK+ALCL is
chromosomal translocations or inversions involving the
ALK tyrosine kinase gene [23,24]. These chromosomal al-
terations generate oncogenic fusion proteins, the most
common being NPM-ALK. NPM-ALK initiates a number
of down-stream signalling events that ultimately promote
the proliferation, survival, and migration of ALK+ALCL
tumour cells [25,26]. In previous work, we demonstrated
that GzB transcription is promoted by NPM-ALK signal-
ling in ALK+ALCL, largely through the AP-1 family tran-
scription factor, JunB [27].
Given that ALK+ ALCL tumour cells exhibit high
levels of apoptosis [28-30] and the observed correlation
between GzB expression and apoptosis rate in nasal-type
NK/T lymphomas [12] and prostate cancer cell lines
[18], we decided to investigate whether GzB expression
might sensitize ALK+ ALCL cells to apoptosis. We dem-
onstrate that short-hairpin RNA (shRNA)-mediated
knock-down of GzB in ALK+ ALCL cell lines is associ-
ated with decreased GzB enzymatic activity. Further-
more, we show that while knock-down of GzB does not
influence spontaneous apoptosis in ALK+ ALCL cell
lines, it reduces drug-induced apoptosis in these cells.
GzB is one of five human granzymes, and all of these
proteins have been implicated in promoting pro-
grammed cell death. Therefore, we examined whether
other granzymes were expressed in these cell lines and
found that GzB is the only human granzyme expressed
at significant levels. In sum, our findings demonstrate
that a well-known phenotypic characteristic of ALK+
ALCL may be an important factor underlying the ability
to treat this lymphoma.
Results
GzB protein levels and activity are significantly reduced in
ALK+ ALCL cell lines treated with GzB shRNA
In order to examine whether GzB sensitizes ALK+ALCL to
apoptosis, we generated ALK+ALCL cell lines where GzB
expression had been stably knocked-down with shRNA. We
generated these knock-down cells in multiple ALK+ALCL
cell lines (Karpas 299, SUP-M2, and SR (also known as SR-
786)) and used shRNAs that target different regions of the
GzB gene. Analysis of GzB knock-down by western blotting
(Figure 1A) or flow cytometry (Figure 1B) demonstrated
that GzB protein levels were significantly reduced in cells
expressing GzB shRNAs compared to cells expressing a
non-targeting control shRNA. Quantification of the mean
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Figure 1 Knock-down of GzB in ALK+ALCL cell lines. Western blots (A) or flow cytometry plots (B) comparing the expression of GzB in ALK+ALCL cell
lines stably expressing either a non-targeting (control) shRNA or the indicated GzB shRNAs. Molecular mass standards are indicated to the left of the western blots.
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protein levels in the GzB knock-down cells were 18 to 49%
of the levels in cells expressing the non-targeting shRNA
(Table 1). Of note, GzB knock-down cell lines had a similar
growth rate as cells expressing control shRNA (Figure 2).Table 1 Quantification of GzB levels in ALK+ ALCL cell lines e
Cell line shRNA construct
Karpas 299 GzB shRNA #1
GzB shRNA #2
GzB shRNA #3
SR GzB shRNA #1
SUP-M2 GzB shRNA #1
GzB shRNA #3
The relative mean fluorescence intensity of GzB staining in Karpas 299, SR, or SUP-M
cells expressing control, non-targeting shRNA is indicated. The values shown represGzB knock-down resulted in markedly reduced GzB en-
zymatic activity as measured by the ability of lysates from
these cells to cleave the synthetic GzB substrate, Ac-IEPD-
pNA (Figure 3A). Moreover, in Karpas 299 cell lysates the
reduction in Ac-IEPD-pNA cleavage roughly correlatedxpressing GzB shRNA







2 cells stably expressing the indicated GzB shRNA constructs compared to
ent the average and standard deviation of 3 independent experiments.
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and 3A). Lysates from cells where GzB was knocked-down
also had reduced ability to cleave the GzB substrate, vitro-
nectin [5] (Figure 3B).
GzB sensitizes ALK+ ALCL cell lines to staurosporine-
induced apoptosis
GzB expression has been argued to contribute to apop-
tosis induction in nasal-type NK/T cell lymphoma [12]
and prostate cancer cells [18]. Therefore, we investigated
whether the expression of GzB in ALK+ ALCL cells
might sensitize these cells to spontaneous or drug-
induced apoptosis. As a measure of apoptosis, we first
examined cleavage of PARP which is a substrate of exe-
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Figure 2 Knock-down of GzB in ALK+ ALCL cell lines does not affect g
cells expressing the indicated GzB shRNA was compared to control shRNA-ex
of 3 (SUP-M2) or 4 (Karpas 299 and SR) independent experiments. The only tim
the GzB and control shRNA-expressing cell lines was at the 48 h time point w
the control shRNA-expressing cells (p = 0.042).observed no difference in PARP cleavage between ly-
sates of DMSO-treated Karpas 299 cells expressing
control or GzB shRNAs, at low doses of staurosporine
treatment (particularly at 0.15 and 0.2 μM) PARP cleav-
age was less prominent in lysates from cells with GzB
knocked-down compared to cells expressing control
shRNA (Figure 4A). A similar reduction in PARP cleav-
age at low doses of staurosporine treatment was ob-
served in lysates of SR (Figure 4B) and SUP-M2
(Figure 4C) cells expressing GzB shRNA; albeit the dif-
ference in PARP cleavage between GzB and control
shRNA-expressing cells in the SUP-M2 line was less
pronounced. At higher staurosporine concentrations,





















rowth rate. The growth rate of Karpas 299 (A), SUP-M2 (B), or SR (C)
pressing cells. The results represent the average and standard deviation
e point where we observed a statistically significant difference between
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Figure 3 ALK+ ALCL cell lines with GzB knock-down show significant reduction in GzB activity. A. Cleavage of the synthetic GzB substrate,
Ac-IEPD-pNA, was examined using lysates from the indicated ALK+ ALCL cell lines expressing either control or GzB shRNA. The results represent the
average and standard deviation of 3 independent experiments. p values comparing cells expressing GzB shRNA to cells expressing control shRNA were
obtained by performing paired, one-tailed t-tests. *p < 0.05, **p < 0.01, ***p < 0.005. B. Lysates from Karpas 299 cells (above) or SUP-M2 cells (below)
expressing the indicated shRNAs were incubated with purified vitronectin for the indicated times and vitronectin cleavage was examined by western
blotting. Arrows indicate the major observed vitronectin cleavage product. Cleavage of vitronectin was also examined when incubated with
lysates from the GzB-negative, Hodgkin lymphoma cell line, KM-H2, which served as a negative control. Anti-β-actin blots were performed to
demonstrate that equivalent amounts of lysate were added to the reactions. The percentage of cleaved vitronectin (% cleaved vitronectin)
was determined by densitometry, and represents the percentage of cleaved vitronectin in each lane relative to cleaved vitronectin in the lane
where vitronectin was incubated with control shRNA lysate for 6 h. Molecular mass standards are indicated to the left of the western blots.
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the sensitivity of ALK+ ALCL cell lines to staurosporine-
induced apoptosis and to better quantify this difference,
we examined the effect of GzB knock-down on the de-
gree of terminal deoxynucleotidyl transferase dUTP nick
end labelling (TUNEL)-positive staining in ALK+ ALCL
cell lines treated with staurosporine. TUNEL staining
measures the characteristic DNA fragmentation of apop-
totic cells [34,35]. Similar to our PARP cleavage data, we
found that GzB knock-down had no effect on TUNEL-
positive staining in untreated Karpas 299 cells (Figure 4D);however, at lower concentrations of staurosporine treat-
ment (0.15 and 0.2 μM), we observed a 30-50% reduction
in the percentage of TUNEL-positive cells in the GzB
shRNA-expressing cells compared to the control shRNA-
expressing cells (Figure 4D). A ~30% decrease in the per-
centage of TUNEL-positive cells was also observed in SR
cells at lower doses of staurosporine treatment (0.1 and
0.15 μM) when GzB was knocked-down (Figure 4E). We
even noted a modest decrease (~14%) in the percentage of
TUNEL-positive cells in SR cells with reduced GzB levels
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PARP
Figure 4 GzB knock-down reduces the sensitivity of ALK+ ALCL cell lines to staurosporine-induced apoptosis. Karpas 299 (A), SR (B), or
SUP-M2 (C) cells expressing either control or GzB shRNA were left untreated (DMSO) or were treated with the indicated concentrations of staurosporine
(STS) for 6 h at 37°C. Lysates were then prepared and western blotted with an anti-PARP antibody. The arrow indicates cleaved PARP. The anti-β-actin blot
demonstrates equivalent protein loading. The percentage of cleaved PARP (% cleaved PARP) was determined by densitometry and represents
the percentage of cleaved PARP as a fraction of total PARP. Molecular mass standards are indicated to the left of the western blots. Karpas 299
(D) or SR (E) cells expressing either control or GzB shRNA were left untreated (DMSO) or were treated with the indicated concentrations of
staurosporine (STS) for 6 h at 37°C. DNA fragmentation was then examined by TUNEL staining and results were expressed as the percentage of TUNEL-
positive cells. The results shown represent the mean and standard deviation of at least 4 (Karpas 299) or 5 (SR) independent experiments. p values
comparing cells expressing GzB shRNA to cells expressing control shRNA were obtained by performing paired, one-tailed t-tests. *p< 0.05, § p< 0.01,
# p< 0.005, δ p< 0.001.
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that GzB sensitizes ALK+ALCL cell lines to staurosporine-
induced apoptosis; however, at higher staurosporine con-
centrations GzB expression does not appear to significantly
contribute to apoptosis induction.GzB sensitizes the SUP-M2 and SR ALK+ ALCL cell lines to
doxorubicin-induced PARP cleavage
Doxorubicin is a DNA damaging agent that induces apop-
tosis in ALK+ALCL cell lines [36], and is one component
of the CHOP (cyclophosphamide, hydroxydaunorubicin
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regimen often used to treat ALK+ALCL patients [37-39].
Therefore, we investigated whether GzB also sensitized
ALK+ALCL cells to doxorubicin-induced apoptosis. In
both SUP-M2 (Figure 5A) and SR (Figure 5B) cells, we ob-
served reduced PARP cleavage in response to doxorubicin
treatment in the GzB shRNA-expressing cells compared
to control shRNA-expressing cells. Moreover, we also ob-
served a decrease in the percentage of TUNEL positive cells
in GzB knockdown SUP-M2 (Figure 5C) and SR (Figure 5D)
cells. Thus, the increased sensitivity to drug-induced apop-
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Figure 5 GzB knock-down reduces the sensitivity of ALK+ ALCL cell li
expressing either control or GzB targeting shRNA were left untreated (untr.
for 12 h at 37°C. Cells were then lysed and lysates were probed with an an
blot demonstrates equivalent protein loading. The percent cleaved PARP (%
percentage of cleaved PARP as a fraction of total PARP. Molecular mass sta
(D) cells expressing either control or GzB shRNA were left untreated (DMSO
(doxo) for 12 h at 37°C. DNA fragmentation was then examined by TUNEL
positive cells. The results shown represent the mean and standard deviatio
GzB shRNA to cells expressing control shRNA were obtained by performingOver-expression of GzB increases the sensitivity of the
Karpas 299 cell line to staurosporine-induced apoptosis
Since knock-down of GzB reduced the sensitivity of ALK+
ALCL cell lines to drug-induced apoptosis, we examined
whether GzB over-expression might further sensitize these
cells to drug induced apoptosis. We chose the Karpas 299
cell line because this line possesses the least amount of en-
dogenous GzB, and in our hands, is the most efficiently
transfected ALK+ALCL cell line (results not shown).
Transfection of Karpas 299 cells with a GzB cDNA resulted
in a ~4-8-fold increase in GzB expression (Figure 6A).
Using TUNEL to measure apoptosis induction, we found



























































nes to doxorubicin-induced apoptosis. SUP-M2 (A) or SR (B) cells
) or were treated with indicated concentrations of doxorubicin (Doxo)
ti-PARP antibody. The arrow indicates cleaved PARP. The anti-β-actin
cleaved PARP) was determined by densitometry and represents the
ndards are indicated to the left of the western blots. SUP-M2 (C) or SR
) or were treated with the indicated concentrations of doxorubicin
staining and results were expressed as the percentage of TUNEL-
n of 4 independent experiments. p values comparing cells expressing
paired, one-tailed t-tests. *p < 0.05, § p < 0.01, # p < 0.005, δ p < 0.001.
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transfected with vector alone (Figure 6B). These findings
further implicate GzB expression as a sensitizing factor to
drug-induced apoptosis in ALK+ALCL cell lines.
GzB is the only granzyme expressed at significant levels
in ALK+ ALCL cell lines
There are five human granzymes (A, B, H, K, and M)
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Figure 6 GzB over-expression increases the sensitivity of Karpas
299 cells to staurosporine-induced apoptosis. A. Representative
flow cytometry plot showing GzB expression in Karpas 299 cells
transfected with either a GzB cDNA (red line) or vector alone blue
line). The shaded histogram indicates cells stained with an irrelevant
isotype control antibody. The numbers above each peak represent
the mean fluorescence intensity of GzB staining in vector and GzB
cDNA transfected cells. B. Cells in A. were treated for 6 h with
staurosporine at the indicated concentrations and apoptosis was
measured by TUNEL. The results represent the average and standard
deviation of 5 independent experiments. p values comparing cells
transfected with GzB cDNA to cells transfected with vector alone were
obtained by performing paired, one-tailed t-tests. *p < 0.05, § p < 0.01.purified protein to cells along with perforin or another
agent to deliver the granzyme into the cytosol of the
target cell [40-47]. While data demonstrating the im-
portance of some of these granzymes in mediating cell
death in vivo is lacking, GzA has been implicated in the
killing of target cells by CTL and NK cells via a mechan-
ism that shares many characteristics with GzB-induced
apoptosis [48-50]. Furthermore, NK cells can use GzK to
kill activated T cells [51]. Therefore, we investigated
whether other human granzymes might also sensitize
ALK+ ALCL cell lines to cell death. Since, to our know-
ledge, the expression of the granzymes A, H, K, and M
has not been described in this lymphoma, we performed
reverse transcriptase-polymerase chain reaction (RT-
PCR) to examine whether they are expressed in ALK+
ALCL cell lines. The NK cell lines, NKL and NK-92,
express multiple human granzymes and were used as
positive controls [52,53], whereas the HCT 116 colorec-
tal carcinoma cell line was used as a negative control
for granzyme expression. RT-PCR analysis of RNA col-
lected from these cell lines demonstrated that four of
the five ALK+ ALCL cell lines (Karpas 299, SU-DHL-1,
SR and UCONN) expressed detectable levels of GzA
mRNA (Figure 7A). In contrast, we did not detect GzH,
GzK or GzM mRNA in any of the ALK+ ALCL cell
lines, but the expression of these genes was readily de-
tected in either the NK-92 or NKL cell lines (Figure 7A).
GzB expression was observed in all the ALK+ ALCL
cell lines.
We next performed western blotting experiments to
examine the expression of GzA protein in ALK+ ALCL
cell lines. Surprisingly, while we could detect GzA pro-
tein in NKL cell lysates, we did not observe GzA protein
expression in lysates from any of the ALK+ ALCL cell
lines (Figure 7B). As expected, GzB protein was detected
in all the ALK+ ALCL cell lines. To resolve this discrep-
ancy between our ability to detect GzA expression at the
mRNA but not the protein level, we compared GzA
mRNA levels between the ALK+ ALCL cell lines and
NKL cells using quantitative real time-polymerase chain
reaction (qRT-PCR). Because the different cell lines
could express varying levels of individual housekeeping
genes, we normalized our data to both GAPDH and
β-tubulin. Our results showed that the ALK+ ALCL cell
lines expressed substantially less GzA mRNA than NKL
cells, with similar results obtained when GzA levels were
normalized to each housekeeping gene (Figure 7C). This
finding suggests that our inability to detect GzA protein in
the ALK+ALCL cell lines is likely due to the low GzA
transcript levels in these cells. In sum, the results of these
experiments demonstrate that GzB is the only granzyme
expressed at significant levels in these ALK+ALCL cell
lines and therefore, is the only granzyme that could be























































































































































































Figure 7 Expression of granzymes in ALK+ ALCL cell lines. A. RT-PCR was performed on RNA isolated from the indicated ALK+ ALCL cell lines
to examine the expression of the indicated genes. RNA isolated from the NKL (human NK leukemia) and NK-92 (human NK lymphoma) cells served as
positive controls for granzyme expression, whereas RNA isolated from HCT116 (human colon carcinoma) cells served as a negative control. In the
“no template” sample, no template cDNA was used in the PCR reaction. Base pair standards are indicated to the left of images. B. Western blot analysis
examining GzA and GzB expression in the lysates of ALK+ ALCL cell lines. The KM-H2 cell line (Hodgkin lymphoma) serves as a negative control, while
the NKL cell line serves as a positive control for GzA protein expression. Molecular mass standards are indicated to the left of the western blots. C.
Quantitative RT-PCR was performed to compare GzA mRNA expression levels between the ALK+ ALCL cell lines and the NKL cell line. The results were
normalized to either β-tubulin (left) or GAPDH (right) levels. The results represent the average and standard deviation of three independent experiments.
ND = not detected.
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In this report, we provide evidence linking the expres-
sion of GzB to apoptosis sensitivity in ALK+ ALCL. We
show that knock-down of GzB in multiple ALK+ ALCL
cell lines using several distinct GzB shRNAs resulted in
reduced apoptosis following treatment with low doses of
staurosporine. This was demonstrated by a reduction in
both PARP cleavage and the percentage of TUNEL-
positive cells (Figure 4). Moreover, we observed increased
staurosporine-induced apoptosis in Karpas 299 cells over-
expressing GzB (Figure 6). We also observed a similar im-
pairment in PARP cleavage and reduced TUNEL staining
in SUP-M2 and SR cells lines expressing GzB shRNA fol-
lowing treatment with doxorubicin (Figure 5), a compo-
nent of the combination chemotherapy used to treat
patients with ALK+ALCL [37-39]. Surprisingly, weobserved no impairment in PARP cleavage, and even a
slight enhancement in some experiments, when Karpas
299 cells expressing GzB shRNA were treated with doxo-
rubicin (unpublished observation). Why this is the case is
unclear since we observed a clear effect on doxorubicin-
induced PARP cleavage with GzB knock-down in other
ALK+ALCL cell lines (Figure 5), and found that knocking-
down GzB expression in Karpas 299 cells reduced the sen-
sitivity of these cells to staurosporine-induced apoptosis
(Figure 4A and D). Independent of this one inconsistent
result, our findings strongly implicate GzB expression in
ALK+ALCL as a sensitizing factor to apoptosis-inducing
drugs.
An unresolved question from this study is how GzB
sensitizes ALK+ ALCL cell lines to drug-induced apop-
tosis. In nasal NK/T cell lymphomas GzB has been
Pearson et al. Molecular Cancer 2014, 13:199 Page 10 of 14
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ules and initiate apoptosis [12]. However, since we ob-
served no decrease in apoptosis associated with GzB
knock-down in untreated cells (Figures 4 and 5), it is un-
likely that spontaneous leakage of GzB is contributing to
apoptosis in ALK+ ALCL cell lines. Rather, we favour a
model whereby drug treatment initiates apoptosis in
cells resulting in damage to the cytotoxic vesicles and re-
lease of GzB into the cytosol. This phenomenon has
been observed in CD8+ CTLs induced to undergo apop-
tosis by treatment with the human cathelicidin, LL-37
[54]. Once in the cytosol, we postulate that GzB then
amplifies apoptosis induction. The release of GzB into
the cytosol would be predicted to be particularly detri-
mental in ALK+ ALCL, as tumour cells in ALK+ ALCL
patient samples do not express the GzB inhibitor, pro-
teinase inhibitor-9 (PI-9) [28]. PI-9 is an irreversible in-
hibitor of GzB and it is expressed by cytotoxic cells as a
means of protecting these cells from GzB that enters the
cytoplasm [55]. It is also expressed in some tumour cells
and postulated to be a means by which these cells protect
themselves from being killed by CTLs and NK cells [55].
We have found that PI-9 is either not expressed or
expressed at very low levels in ALK+ALCL cell lines (un-
published observation), and we suspect this is a factor con-
tributing to why GzB sensitizes these cells to apoptosis.
ALK+ALCL patients are usually treated successfully
using standard chemotherapy regimens, and the overall 5-
year survival rate of these patients is 70-85% [37,38,56-58].
One key factor likely impacting favourable prognosis in
this lymphoma is the relatively young age (average age of
16–22) of ALK+ALCL patients [37,58,59]. It is probable
that ALK+ALCL tumours have not acquired many sec-
ondary oncogenic mutations/alterations that would be pre-
dicted to render these tumour cells less susceptible to
chemotherapy. Rather, ALK+ALCL tumour cells are heav-
ily reliant on signalling pathways activated by ALK fusion
proteins, and ALK+ status is a strong favourable prognostic
indicator in ALCL [37,38,56-58,60]. Our results suggest
that the expression of GzB, combined with a lack of PI-9
expression, may be another factor contributing to the
favourable clinical outcome of ALK+ ALCL patients.
Interestingly, a previous study found that cytotoxic
phenotype, as measured by expression of GzB and TIA-1,
did not correlate with clinical outcome in ALCL patients
[9]. However, this study included only 13 ALK+ALCL pa-
tients; almost all which possessed a cytotoxic phenotype
(12 of 13) and all had favourable outcome. Thus, we feel
that a more extensive study investigating whether cyto-
toxic phenotype, and more specifically expression of GzB,
is important in clinical outcome is warranted. Moreover,
since the number of GzB-positive cells vary quite signifi-
cantly in ALK+ALCL patients [8-10], it will be important
to examine whether the degree of GzB expression isclinically relevant in this lymphoma. Regardless of
whether or not GzB expression is prognostic or predictive
of ALK+ALCL outcome, our results clearly demonstrate
that it is a factor contributing to the susceptibility of these
tumour cells to drug-induced apoptosis.
Conclusions
Our findings reveal that GzB expression is more than
just a phenotypic characteristic of ALK+ ALCL lymph-
oma cells, as expression of this serine protease sensitizes
ALK+ ALCL tumour cells to drug-induced apoptosis.
Furthermore, we postulate that this sensitization may be
one factor contributing to the successful treatment and
the favourable outcome of ALK+ ALCL patients.
Methods
Antibodies and other reagents
The mouse monoclonal antibodies against Granzyme B
(2C5), β-actin (AC-15), and PARP (C2-10), as well as the
vitronectin polyclonal antibody (H-270) were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). The
polyclonal antibody to Granzyme A (#4928) was pur-
chased from Cell Signaling Technology (Danvers, MA).
Purified human vitronectin was obtained from BD Bio-
sciences (Mississauga, ON) and the synthetic GzB sub-
strate Ac-IEPD-pNA was purchased from Sigma-Aldrich
(St. Louis, MO). Staurosporine was obtained from Enzo
Life Sciences (Plymouth Meeting, PA) and doxorubicin
was purchased from Sigma-Aldrich.
Cell lines
The Karpas 299 and SUP-M2 ALK+ ALCL cell lines
were purchased from the Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cul-
tures (Braunschweig, Germany). The ALK+ ALCL cell
line SR (also known as SR-786) was obtained from the
American Type Culture Collection (Manassas, VA) and
the SU-DHL-1 and UCONN ALK+ ALCL cell lines
were provided by Dr. Raymond Lai (University of
Alberta, Edmonton, AB, Canada). The Hodgkin lymph-
oma cell line, KM-H2, was generously provided by Dr.
Hesham Amin (University of Texas M. D. Anderson
Cancer Center, Houston, TX). KM-H2 and ALK+ ALCL
cell lines were cultured in RPMI 1640 media supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 1 mM sodium pyruvate (Sigma-Aldrich; St Louis,
MO), 2 mM L-glutamine (Gibco; Burlington, ON,
Canada), and 50 μM 2-mercaptoethanol (BioShop;
Burlington, ON, Canada). The human leukemic NK cell
line, NKL, and the non-Hodgkin lymphoma NK cell line,
NK-92, were generously provided by Dr. Debby Burshtyn
(University of Alberta). NKL cells were cultured in Iscove’s
media supplemented with 2 mM L-glutamine, 10% FBS
and 200 U/ml recombinant human interleukin (IL)-2
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media supplemented with 2 mM L-glutamine, 12.5% FBS,
12.5% horse serum, 36 μg/ml inositol (Sigma Aldrich),
17.6 μg/ml folic acid (Sigma-Aldrich), 100 μM 2-
mercaptoethanol, and 100 U/ml recombinant human IL-
2. The HCT 116 colorectal carcinoma cell line (a gift from
Dr. David Murray; University of Alberta) and HEK 293T
cells were cultured in DMEM supplemented with 10%
FBS, 1 mM sodium pyruvate and 2 mM L-glutamine. All
cells were maintained at 37°C in a 5% CO2 atmosphere.
Generating stable ALK+ ALCL cell lines using lentiviral
transduction
HEK 293T cells were used to generate lentiviral vectors
using the MISSION short hairpin RNA (shRNA) lentiviral
system (Sigma-Aldrich). HEK 293T cells were transfected
with lentiviral packaging vectors along with pLKO.1 vec-
tor containing the shRNA sequence of interest using the
FuGENE HD transfection reagent (Promega; Madison,
WI). The shRNA constructs used were: control, non-
targeting shRNA (SHC002) and three different GzB
shRNA constructs designated #1 (TRCN0000006445), #2
(TRCN0000006448) and #3 (TRCN0000006449). Ap-
proximately 48 h after transfection, lentivirus-containing
supernatant was collected from the transfected HEK 293T
cells and used to infect the ALK+ALCL cell lines. Pooled
populations of stable transfectants were then selected in
0.5 μg/ml puromycin and GzB knock-down was assessed
by western blotting and flow cytometry.
Staurosporine and doxorubicin treatments
To induce apoptosis in ALK+ ALCL cell lines, cells were
counted and resuspended at 4–6x105 cells/ml in
complete RPMI media. Cells were then treated with
0.1% DMSO (untreated) or the indicated concentrations
of staurosporine for 6 h at 37°C. Alternatively, cells were
left untreated or were treated with the indicated concen-
trations of doxorubicin for 12 h at 37°C.
Cell lysis and western blotting
Cells were collected by centrifugation and lysed in Noni-
det P-40 lysis buffer [61] containing protease inhibitor
cocktail (Sigma-Aldrich; Mississauga, ON, Canada), 1 mM
phenylmethylsulfonylfluoride, and 1 mM sodium orthova-
nadate. Lysates were then cleared of detergent-insoluble
material by centrifugation for 10 minutes at ~20,000 g,
and the protein concentration of lysates was determined
using the BCA Protein Assay kit (Thermo Scientific;
Waltham, MA). For western blots, equivalent protein
amounts were resolved on SDS-PAGE gels, transferred to
nitrocellulose membranes, probed with the indicated anti-
bodies and then visualized using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific). Reprobed
blots were first stripped in 0.1% TBST, pH 2 and thenprobed with the new primary antibody. The amount of
cleaved PARP or vitronectin was quantified by densitom-
etry using ImageJ software (NIH, Bethesda, MD).
Analysis of GzB expression using flow cytometry
Cells (~4x105) were collected by centrifugation and
permeabilized using BD Cytofix/Cytoperm solution (BD
Biosciences; Mississauga, ON, Canada) for 20 min on
ice. Cells were washed once in BD Perm/Wash buffer
(BD Biosciences) and resuspended in BD Perm/Wash buffer
containing 1:250 diluted APC-conjugated anti-GzB (clone
GB12) or isotype control antibody (Invitrogen; Burlington,
ON, Canada). Cells were incubated with the antibody for
30 min on ice, washed once with BD Perm/Wash buffer
and analysed by flow cytometry using a BD FACSCalibur
(Figure 1) or a BD LSR Fortessa (Figure 6) flow cytometer
(BD Biosciences). Data were analysed using CellQuest Pro
(BD Biosciences), FACSDiva (BD Biosciences), and FlowJo
software (Tree Star Inc.; Ashland, OR).
Measuring the growth rate of cell lines
Cells (5x104/ml) were plated in fresh media and cell via-
bility was measured in triplicate each day using a
Resazurin-based assay [62] on a FLUOstar OPTIMA mi-
croplate reader (BMG Labtech; Ortenberg, Germany).
Cleavage of the synthetic GzB substrate, Ac-IEPD-pNA
The level of GzB activity present in ALK+ALCL cell ly-
sates was assessed by measuring cleavage of the synthetic
GzB substrate, Ac-IEPD-pNA, as previously described
[63]. Cells were lysed at a concentration of 5x107 cells/ml
as outlined above, with the exception that protease inhibi-
tors were omitted from the lysis buffer. Lysates were then
incubated with 200 μM Ac-IEPD-pNA at 37°C for 30 min
and absorbance was measured at 405 nm using a BMG
Labtech FLUOstar OPTIMA microplate reader (Ortenberg,
Germany). Each sample was assayed in triplicate and the
triplicate measurements were averaged. Results are pre-
sented relative to the activity present in lysate from cells ex-
pressing control shRNA, which was set to 100%.
Vitronectin cleavage assays
Wells of a 96-well plate were coated with 0.5 μg of puri-
fied human vitronectin (suspended in 50 μl of 1X PBS)
at 4°C overnight. Wells were then blocked with 2% BSA
(in 50 μl of 1X PBS) for 1 hr at 37°C, and washed twice
with 1X PBS. The indicated cell lines were then lysed at
5x107 cells/ml in lysis buffer lacking protease inhibitors,
and 50 μl of cell lysate was added to the coated wells.
Plates were then incubated at 37°C for the indicated
times, at which time the reactions were stopped by the
addition of SDS-PAGE sample buffer. Samples were re-
solved using SDS-PAGE and vitronectin cleavage was
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nectin was quantified by densitometry using ImageJ
software.
TUNEL
Apoptosis was assayed in staurosporine-treated cells
using TUNEL with the In Situ Cell Death Detection Kit,
Fluorescein (Roche Applied Science; Laval, QC, Canada)
as outlined in the manufacture’s protocol. Following
TUNEL staining, cells were analysed using a FACSCali-
bur or a BD LSR Fortessa flow cytometer to determine
the percentage of dUTP-positive cells.
Transfection of Karpas 299 cells
1x107 Karpas 299 cells were transfected with 50 μg of GzB
cDNA in pcDNA 3.1A (Invitrogen) or 50 μg of pcDNA
3.1A alone as previously described [64] using a BTX square
wave electroporator (Harvard Apparatus; Holliston MA).
48 h post-transfection, cells were treated with staurosporine
and apoptosis was analysed by TUNEL as described above.
RNA extraction and RT-PCR analysis
Total RNA was collected from the indicated cell lines
using the RNeasy mini kit (Qiagen; Mississauga, ON).
The RNA was then digested with DNase I, and con-
verted to cDNA using the Superscript II Reverse Tran-
scriptase System (Invitrogen). The cDNA that was
generated was then subjected to PCR using the following
primer sets: GzB forward - TGC GAA TCT GAC TTA
CGC CAT, reverse - GGA GGC ATG CCA TTG TTT
CG; GzA forward - CAT CTG TGC TGG GGC TTT
GA, reverse - GAG GCT TCC AGC ACA AAC CA;
GzH forward - GCA AGA GAA GAG TCG GAA GAG
G, reverse - AAC CCC AGC CAG CCA CAC; GzK for-
ward - CGT TTG TGG AGG TGT TCT GAT TG, re-
verse - CAG TGA CTT CTC GCA GGG TG; GzM
forward - GCG GGG GTG TCC TGG TG, reverse -
ATG CTG GGG GAG AGG CTG; and GAPDH forward
- GAC AGT CAG CCG CAT CTT CT, reverse - TTA
AAA GCA GCC CTG GTG AC. PCR products were re-
solved using agarose gel electrophoresis and visualized
by staining with SYBR Safe DNA gel stain (Invitrogen).
qRT-PCR analysis
RNA was collected and converted to cDNA as described
above. qRT-PCR was performed using PerfeCTa SYBR
Green FastMix (Quanta Biosciences; Gaithersburg, MD)
on a Bio-Rad CFX96 Real-Time PCR Detection System
(Bio-Rad). GzA mRNA levels were then determined
using the ΔΔ-CT method [65] with β-tubulin or GAPDH
as the housekeeping genes. The following primer sets
were used: GzA forward - CAT CTG TGC TGG GGC
TTT GA, reverse - TCT GTT TTG TTG GCT CTT
CCC T; GAPDH forward - GAC AGT CAG CCG CATCTT CT, reverse - TTA AAA GCA GCC CTG GTG
AC; and β-tubulin forward - CAG GCT GGT CAG
TGT GGC A, reverse - CAG GAT GGC ACG AGG
AAC.
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